StemSight Collaboration
Corneal Blindness
Pre-clinicalActive
Key Facts
About Mytos
Mytos is an automated CDMO for regenerative medicine, leveraging its iDEM™ automation platform to reduce the cost and labor of cell therapy manufacturing. The company targets the critical bottleneck of scalable production for clinical-stage biotechs, offering a 'one-stop-shop' from process development to regulatory support. Backed by over $24M in funding and strategic partnerships with organizations like the CGT Catapult, Mytos aims to make curative cell therapies commercially viable and widely accessible.
View full company profile